Daiichi Sankyo

News

EMA starts review of Enhertu for HER2+ gastric cancer

The EMA has started its review of AstraZeneca and Daiichi Sankyo's Enhertu for a second indication, as a second-line treatment for HER2-positive gastric cancer.

News

First launch for Daiichi Sankyo's oncolytic virus Delytact i...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer.

News

AZ/Daiichi partner with Merck on first-line lung cancer tria...

The dominance of Merck & Co's Keytruda in the treatment of previously-untreated non-small cell lung cancer (NSCLC) means it will be hard to dislodge – so AstraZeneca and Daiichi Sankyo

News

Enhertu nabs speedy FDA review for earlier use in breast can...

Hard on the heels of impressive new data for Enhertu as a second-line therapy for breast cancer, AstraZeneca and Daiichi Sankyo have claimed FDA breakthrough status for the drug that should

News

ESMO21: Enhertu brings it’s A game to second-line breast can...

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche's rival Kadcyla when they reported top-line r

News

Daiichi Sankyo claims first okay for oncolytic virus in Japa...

Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer based on a virus that selectively kills malig

EMA starts review of Enhertu for HER2+ gastric cancer

First launch for Daiichi Sankyo's oncolytic virus Delytact i...

AZ/Daiichi partner with Merck on first-line lung cancer tria...

Enhertu nabs speedy FDA review for earlier use in breast can...

ESMO21: Enhertu brings it’s A game to second-line breast can...

Daiichi Sankyo claims first okay for oncolytic virus in Japa...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Daiichi Sankyo

Editor's Picks